Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Stockholders' Equity (Unaudited)

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)	Total	Offering	Common Stock	Common Stock Offering	Additional Paid-In Capital	Additional Paid-In Capital Offering	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning balance at Dec. 31, 2020	$ 9,784,356		$ 10,051		$ 24,805,929			$ (15,031,624)
Beginning balance, Shares at Dec. 31, 2020			10,050,849
Stock-based compensation expense	591,124				591,124
Warrant expense	237,768				237,768
Issuance of common stock	60,391		$ 9		60,382
Issuance of common stock, Shares			9,000
Net loss	(2,637,068)							(2,637,068)
Ending balance at Mar. 31, 2021	8,036,571		$ 10,060		25,695,203			(17,668,692)
Ending balance, Shares at Mar. 31, 2021			10,059,849
Beginning balance at Dec. 31, 2020	9,784,356		$ 10,051		24,805,929			(15,031,624)
Beginning balance, Shares at Dec. 31, 2020			10,050,849
Warrant expense	658,945
Net loss	(9,744,444)
Ending balance at Sep. 30, 2021	43,161,479		$ 25,155		67,912,392			(24,776,068)
Ending balance, Shares at Sep. 30, 2021			25,155,198
Beginning balance at Mar. 31, 2021	8,036,571		$ 10,060		25,695,203			(17,668,692)
Beginning balance, Shares at Mar. 31, 2021			10,059,849
Stock-based compensation expense	322,483				322,483
Warrant expense	239,415				239,415
Issuance of common stock		$ 41,135,357		$ 15,000		$ 41,120,357
Issuance of common stock, Shares				15,000,000
Issuance of common stock, stock options exercised	(43,295)		$ 74		(43,369)
Issuance of common stock, stock options exercised, Shares			73,496
Net loss	(2,636,179)							(2,636,179)
Ending balance at Jun. 30, 2021	47,054,352		$ 25,134		67,334,089			(20,304,871)
Ending balance, Shares at Jun. 30, 2021			25,133,345
Stock-based compensation expense	352,419				352,419
Warrant expense	181,762				181,762
Issuance of common stock, cashless warrant exercise Shares			21,853
Issuance of common stock, cashless warrant exercise	44,143		$ 21		44,122
Net loss	(4,471,197)							(4,471,197)
Ending balance at Sep. 30, 2021	43,161,479		$ 25,155		67,912,392			(24,776,068)
Ending balance, Shares at Sep. 30, 2021			25,155,198
Beginning balance at Dec. 31, 2021	$ 38,415,549		$ 25,155		68,208,081			(29,817,687)
Beginning balance, Shares at Dec. 31, 2021	25,155,198		25,155,198
Stock-based compensation expense	$ 123,229				123,229
Issuance of common stock	67,000		$ 50		66,950
Issuance of common stock, Shares			50,000
Issuance of common stock, stock options exercised	44,142		$ 22		44,120
Issuance of common stock, stock options exercised, Shares			21,853
Net loss	(4,640,601)							(4,640,601)
Ending balance at Mar. 31, 2022	34,009,319		$ 25,227		68,442,380			(34,458,288)
Ending balance, Shares at Mar. 31, 2022			25,227,051
Beginning balance at Dec. 31, 2021	$ 38,415,549		$ 25,155		68,208,081			(29,817,687)
Beginning balance, Shares at Dec. 31, 2021	25,155,198		25,155,198
Warrant expense	$ 0
Net loss	(13,775,103)
Ending balance at Sep. 30, 2022	$ 25,136,200		$ 25,227		68,676,935		26,828	(43,592,790)
Ending balance, Shares at Sep. 30, 2022	25,227,051		25,227,051
Beginning balance at Mar. 31, 2022	$ 34,009,319		$ 25,227		68,442,380			(34,458,288)
Beginning balance, Shares at Mar. 31, 2022			25,227,051
Stock-based compensation expense	132,767				132,767
Net loss	(4,639,939)							(4,639,939)
Ending balance at Jun. 30, 2022	29,502,147		$ 25,227		68,575,147			(39,098,227)
Ending balance, Shares at Jun. 30, 2022			25,227,051
Stock-based compensation expense	101,788				101,788
Other comprehensive income	26,828						26,828
Net loss	(4,494,563)							(4,494,563)
Ending balance at Sep. 30, 2022	$ 25,136,200		$ 25,227		$ 68,676,935		$ 26,828	$ (43,592,790)
Ending balance, Shares at Sep. 30, 2022	25,227,051		25,227,051